

**FOR IMMEDIATE RELEASE**

**For further information contact:**  
Amy Sarli, CSA Medical  
+1-781-538-4779 / [asarli@csamedical.com](mailto:asarli@csamedical.com)

**CSA Medical to Feature the Rapid AV Catheter at American College of Gastroenterology (ACG);  
Announces Presentations of truFreeze® Clinical Studies at the Conference**

**Boston, MA – October 13, 2017:** CSA Medical will feature the new Rapid AV catheter in the exhibit hall and hands-on workshops at ACG 2017 in Orlando, FL. This new catheter, which is used with the truFreeze System, results in a 50% reduction in time to liquid nitrogen spray delivery to the treatment site, thus decreasing overall treatment time.

In addition, a number of new clinical data presentations related to the truFreeze® Spray Cryotherapy (SCT) system used in Barrett’s Esophagus and Esophageal Cancer studies will be presented at the ACG conference. [A full list of abstracts and presentations](#) related to the truFreeze System are available on the CSA Medical website.

“This is an exciting time for the truFreeze franchise with the recent expansion of the truFreeze label and the release of the Rapid AV Catheter. The recent label expansion to include the ablation of Barrett’s Esophagus with high grade dysplasia and/or low grade dysplasia in addition to the ablation of malignant disease provides physicians the ability to ablate a variety of benign and malignant lesions in the esophagus with just one device. The availability of the Rapid AV Catheter enables a faster treatment time,” says Ellen Sheets MD, CEO and President of CSA Medical.

**About CSA Medical**

CSA Medical, Inc. develops and manufactures a proprietary interventional spray cryotherapy technology platform utilizing unique properties of liquid nitrogen spray delivered by a software driven device with specialty catheters that enable delivery of spray cryogen inside the body to flash freeze and destroy unwanted tissue allowing for a rejuvenative pattern of healing. CSA manufactures and distributes this technology in the USA as the truFreeze® system which is currently used to ablate benign (e.g. Barrett’s Esophagus with high grade dysplasia) and malignant lesions.

To learn more about our technology, please visit [www.csamedical.com](http://www.csamedical.com).

truFreeze is a registered trademark of CSA Medical, Inc.